Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

NCT07712536 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)

Interventions

DRUG: QY201 Tablets（10mg）
DRUG: QY201 Tablets（20mg）

Sponsor

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.